1. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.

    The Lancet 385(9973):1107 (2015) PMID 25591505

    Direct-acting antiviral drugs have a high cure rate and favourable tolerability for patients with hepatitis C virus (HCV). Shorter courses could improve affordability and adherence. Sofosbuvir and ledipasvir with ribavirin have high efficacy when taken for 8 weeks but not for 6 weeks. We assesse...
  2. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study

    The Lancet 385(9973):1107 (2015)

    Background Direct-acting antiviral drugs have a high cure rate and favourable tolerability for patients with hepatitis C virus (HCV). Shorter courses could improve affordability and adherence. Sofosbuvir and ledipasvir with ribavirin have high efficacy when taken for 8 weeks ...
  3. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.

    The Lancet 385(9973):1107 (2015) PMID 25591505

    Direct-acting antiviral drugs have a high cure rate and favourable tolerability for patients with hepatitis C virus (HCV). Shorter courses could improve affordability and adherence. Sofosbuvir and ledipasvir with ribavirin have high efficacy when taken for 8 weeks but not for 6 weeks. We assesse...
  4. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.

    The Lancet 385(9973):1107 (2015) PMID 25591505

    Direct-acting antiviral drugs have a high cure rate and favourable tolerability for patients with hepatitis C virus (HCV). Shorter courses could improve affordability and adherence. Sofosbuvir and ledipasvir with ribavirin have high efficacy when taken for 8 weeks but not for 6 weeks. We assesse...
  5. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.

    The Lancet 385(9973):1107 (2015) PMID 25591505

    Direct-acting antiviral drugs have a high cure rate and favourable tolerability for patients with hepatitis C virus (HCV). Shorter courses could improve affordability and adherence. Sofosbuvir and ledipasvir with ribavirin have high efficacy when taken for 8 weeks but not for 6 weeks. We assesse...
  6. Treatment of hepatitis C virus infection.

    Annals of Internal Medicine 162(6):459 (2015) PMID 25775329

  7. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.

    Hepatology 61(3):790 (2015) PMID 25203718 PMCID PMC4340816

    Hepatitis C virus (HCV) modulates intrahepatic cholesterol biosynthetic pathways to promote viral replication. Chronic HCV infection is associated with altered metabolism, including dyslipidemia and insulin resistance (IR), which contributes to disease progression and influences response to ther...
  8. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.

    Hepatology 61(3):790 (2015) PMID 25203718 PMCID PMC4340816

    Hepatitis C virus (HCV) modulates intrahepatic cholesterol biosynthetic pathways to promote viral replication. Chronic HCV infection is associated with altered metabolism, including dyslipidemia and insulin resistance (IR), which contributes to disease progression and influences response to ther...
  9. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.

    Hepatology 61(3):790 (2015) PMID 25203718 PMCID PMC4340816

    Hepatitis C virus (HCV) modulates intrahepatic cholesterol biosynthetic pathways to promote viral replication. Chronic HCV infection is associated with altered metabolism, including dyslipidemia and insulin resistance (IR), which contributes to disease progression and influences response to ther...
  10. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.

    Hepatology 61(3):790 (2015) PMID 25203718 PMCID PMC4340816

    Hepatitis C virus (HCV) modulates intrahepatic cholesterol biosynthetic pathways to promote viral replication. Chronic HCV infection is associated with altered metabolism, including dyslipidemia and insulin resistance (IR), which contributes to disease progression and influences response to ther...
  11. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.

    Hepatology 61(3):790 (2015) PMID 25203718

    Hepatitis C virus (HCV) modulates intrahepatic cholesterol biosynthetic pathways to promote viral replication. Chronic HCV infection is associated with altered metabolism, including dyslipidemia and insulin resistance (IR), which contributes to disease progression and influences response to ther...
  12. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.

    JAMA 313(12):1232 (2015) PMID 25706232

    There is an unmet need for interferon- and ribavirin-free treatment for chronic hepatitis C virus (HCV) infection in patients co-infected with human immunodeficiency virus (HIV). To evaluate the rates of sustained virologic response (SVR) and adverse events in previously untreated patients with ...
  13. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.

    JAMA 313(12):1232 (2015) PMID 25706232

    There is an unmet need for interferon- and ribavirin-free treatment for chronic hepatitis C virus (HCV) infection in patients co-infected with human immunodeficiency virus (HIV). To evaluate the rates of sustained virologic response (SVR) and adverse events in previously untreated patients with ...
  14. Hiv/Aids.

    Infectious Disease Clinics of North America 28(4):ix (2014) PMID 25455316

  15. HIV/AIDS.

    Infectious Disease Clinics of North America 28(4):ix (2014) PMID 25455316

  16. The authors reply.

    Critical Care Medicine 42(12):e798 (2014) PMID 25402303

  17. The authors reply.

    Critical Care Medicine 42(12):e798 (2014) PMID 25402303

  18. HIV/AIDS.

    Infectious Disease Clinics of North America 28(4):ix (2014) PMID 25455316

  19. Hiv/Aids.

    Infectious Disease Clinics of North America 28(4):ix (2014) PMID 25455316

  20. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.

    Annals of Internal Medicine 161(9):634 (2014) PMID 25364884

    The interferon (IFN)-free regimen of sofosbuvir and ribavirin for 24 weeks was recently approved to treat chronic hepatitis C virus (HCV) genotype 1 (GT-1) infection for patients ineligible for IFN. However, sofosbuvir plus ribavirin therapy is associated with relapse in 15% to 30% of patients w...